Metastatic or Locally Advanced Unresectable Solid Tumors
4 clinical trials · Condition
◉ Watch Metastatic or Locally Advanced Unresectable Solid Tumors
| Record | Firm | Date |
|---|---|---|
| Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (NCT05396833) | EMD Serono Research & Development Institute, Inc. | 2022-06-07 |
| First in Human Study of M1069 in Advanced Solid Tumors (NCT05198349) | EMD Serono Research & Development Institute, Inc. | 2022-03-02 |
| Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) (NCT04170153) | EMD Serono Research & Development Institute, Inc. | 2019-12-20 |
| First-in-Human Study of MS201408-0005A as Single Agent and in Combinations (NCT03306420) | EMD Serono Research & Development Institute, Inc. | 2017-10-03 |
Track Metastatic or Locally Advanced Unresectable Solid Tumors automatically
Every clearance here is in the API, with alerts when new ones post.